As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

JonesTrading analyst Soumit Roy has maintained their bullish stance on JANX stock, giving a Buy rating on October 24. Soumit Roy has given his ...

Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its ...

Novartis reports strong Q3 earnings but faces investor concerns over revenue adjustment and pipeline uncertainties. Learn more about NVS stock here.

The global health landscape is bustling with updates. Romania reports bird flu, Coya Therapeutics reveals positive ...

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key ...

Reports Q3 revenue $12.82B, consensus $12.76B. Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis delivered another quarter of ...

Novartis AG’s best-selling drug and a key new cancer medicine posted disappointing sales last quarter, even as the Swiss drugmaker lifted profit guidance for a third straight quarter.

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Swiss pharmaceutical giant Novartis raised its 2024 financial targets Tuesday after posting rising sales and margins in the third quarter, thanks in part to increased production of a prostate cancer ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.